SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
Scienture Holdings reported preliminary unaudited Q3 2026 revenue of approximately $1.22 million, up 256% from roughly $344,000 in Q2 2026. Growth was driven by the August 2026 commercial launch of REZENOPY and initial wholesale shipments, plus Arbli wholesale unit sales that rose 74% sequentially with new institutional formulary additions.
Key figures
- Revenue
- 1220000
- Guidance
- Management targets profitability in 2027; expects acceleration of top-line growth through 2026 and into 2027
- Q2 2026 revenue
- 344000
- Sequential growth
- 256%
- Preliminary unaudited
- Yes
- Arbli wholesale unit growth
- 74% sequential
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.